Patients not patents: Drug research and development as a public enterprise.
作者信息
Gøtzsche Peter C
机构信息
Nordic Cochrane Centre, Rigshospitalet, Denmark.
出版信息
Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12875. Epub 2018 Jan 5.
Abstract
摘要
相似文献
1
Patients not patents: Drug research and development as a public enterprise.患者而非专利：作为公共事业的药物研发
Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12875. Epub 2018 Jan 5.
2
Evidence Europe 2017. London, UK - February 22-23, 2017.2017年欧洲证据大会。英国伦敦——2017年2月22日至23日。
Drugs Today (Barc). 2017 Mar;53(3):203-207. doi: 10.1358/dot.2017.53.3.2622171.
3
Introduction: pharmaceutical innovation: law & the public's health.引言：药物创新：法律与公众健康
J Law Med Ethics. 2009 Summer;37(2):173-5. doi: 10.1111/j.1748-720X.2009.00363.x.
4
Realizing two-tiered innovation policy through drug regulation.通过药品监管实现两级创新政策。
Stanford Law Rev. 2006 Feb;58(4):1221-50.
5
[The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].[药物的研发过程、临床研究与商业化。限制因素、障碍、延误及成本]
Encephale. 2006 Oct;32(5 Pt 3):S858-60. doi: 10.1016/s0013-7006(06)76246-7.
6
The antibiotic pipeline: reviving research and development and speeding drugs to market.抗生素研发渠道：重振研发并加速药物上市
Expert Rev Anti Infect Ther. 2017 May;15(5):425-433. doi: 10.1080/14787210.2017.1308251. Epub 2017 Mar 29.
7
[Medication prices in Germany--how are they determined?].[德国的药品价格——它们是如何确定的？]
Dtsch Med Wochenschr. 2010 Oct;135(39):p34. doi: 10.1055/s-0030-1247697. Epub 2010 Oct 4.
8
Pharmaceutical pricing conundrum: time to get rid of it?药品定价难题：是时候解决它了吗？
Eur J Health Econ. 2018 Nov;19(8):1035-1038. doi: 10.1007/s10198-018-0995-x.
9
Pharmaceuticals and medical devices: business practices. Issue brief.药品和医疗器械：商业行为。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-36.
10
Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.新西兰的肿瘤学药物资助：一种不同的方法及一项提议。
J Oncol Pract. 2015 May;11(3):249-51. doi: 10.1200/JOP.2014.000083. Epub 2015 Mar 31.
引用本文的文献
1
A totally new system is needed for drug research and development.药物研发需要一个全新的系统。
Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12883. Epub 2018 Jan 16.
本文引用的文献
1
Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review.认知行为疗法可将反复自杀未遂的风险减半：系统评价。
J R Soc Med. 2017 Oct;110(10):404-410. doi: 10.1177/0141076817731904.
2
The Association of Cancer Physicians responds to "Cancer drugs, survival, and ethics".癌症医师协会对《癌症药物、生存与伦理》作出回应。
BMJ. 2016 Dec 5;355:i6487. doi: 10.1136/bmj.i6487.
3
Busting the billion-dollar myth: how to slash the cost of drug development.打破十亿美元神话：如何大幅削减药物研发成本。
Nature. 2016 Aug 25;536(7617):388-90. doi: 10.1038/536388a.
4
"Adaptive pathways" to drug authorisation: adapting to industry?药品批准的“适应性途径”：是在适应制药行业吗？
BMJ. 2016 Aug 16;354:i4437. doi: 10.1136/bmj.i4437.
5
The European Medicines Agency is still too close to industry.欧洲药品管理局与制药行业关系仍过于紧密。
BMJ. 2016 May 6;353:i2412. doi: 10.1136/bmj.i2412.
6
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.基于替代终点及后续总生存期获批的抗癌药物：对美国食品药品监督管理局5年获批情况的分析
JAMA Intern Med. 2015 Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868.
7
Approvals of drugs with uncertain benefit-risk profiles in Europe.在欧洲，批准具有不确定获益-风险特征的药物。
Eur J Intern Med. 2015 Oct;26(8):572-84. doi: 10.1016/j.ejim.2015.08.008. Epub 2015 Sep 3.
8
9
'Choosing Wisely': a growing international campaign.“明智选择”：一项日益发展的国际运动。
BMJ Qual Saf. 2015 Feb;24(2):167-74. doi: 10.1136/bmjqs-2014-003821. Epub 2014 Dec 31.
10
Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.根据附条件合规政策在加拿大获批药物的上市后安全警告。
Br J Clin Pharmacol. 2015 May;79(5):847-59. doi: 10.1111/bcp.12552.
Zotero 插件